Drug Database
Back to search

Belgium· BE-AMP-SAM582275-00

Tysabri 150 mg

A natalizumab product containing natalizumab, registered in Belgium by Biogen Netherlands. The same ATC class is registered in 11 of our 19 countries.

ATC L04AG03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedTysabri 150 mgATCL04AG03REGISTER NO.BE-AMP-SAM582275-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about natalizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Natalizumab is registered in 11 of 19 countries.

Countries holding a registration under ATC L04AG03 (natalizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search natalizumab products by name

Natalizumab · ATC L04AG03

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Natalizumab
Manufacturer
Biogen Netherlands
Country
Belgium (BE)
ATC code
L04AG03
ATC class
Natalizumab
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    7731383
  • be_apb
    4389680
    EUR 1273.39

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

323 interactions on record for natalizumab.

Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check natalizumab against other medicinesHow interaction checks work

Natalizumab · interactions on record

323 records

  • 301 severe
  • 15 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Natalizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All natalizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tyruko, Tysabri
  • Liechtenstein · Tyruko, Tysabri
  • Norway · Tyruko, Tysabri

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4cd68da2-86b6-4608-a73a-c94437c6ecad
GET /v1/drugs/4cd68da2-86b6-4608-a73a-c94437c6ecad?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Tysabri 150 mg",
  "name_fr": "Tysabri 150 mg",
  "name_nl": "Tysabri 150 mg",
  "amp_code": "SAM582275-00",
  "strengths": [
    "150.0000",
    "150.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Natalizumab",
    "Disodium Hydrogen Phosphate Heptahydrate",
    "Sodium Chloride",
    "Sodium Phosphate Monobasic Monohydrate",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Natalizumab",
  "authorisation_numbers": [
    "EU/1/06/346/002",
    "EU/1/06/346/003"
  ]
}
API referenceMCP serverPlans

See everything about natalizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console